AstraZeneca PLC (AZN)vsRapid Micro Biosystems Inc (RPID)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
RPID
Rapid Micro Biosystems Inc
$2.30
-6.50%
HEALTHCARE · Cap: $112.59M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 174786% more annual revenue ($58.74B vs $33.59M). AZN leads profitability with a 17.4% profit margin vs -140.3%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
RPID
Avoid33
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Margin of Safety
-20.3%
Fair Value
$3.49
Current Price
$2.30
$1.19 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Revenue surging 37.3% year-over-year
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -86.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : RPID
The strongest argument for RPID centers on Revenue Growth. Revenue growth of 37.3% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : RPID
The primary concerns for RPID are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
AZN profiles as a value stock while RPID is a hypergrowth play — different risk/reward profiles.
RPID carries more volatility with a beta of 1.60 — expect wider price swings.
RPID is growing revenue faster at 37.3% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 33/100), backed by strong 17.4% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Rapid Micro Biosystems Inc
HEALTHCARE · MEDICAL DEVICES · USA
Rapid Micro Biosystems Inc (RPID) is a pioneering biotechnology firm dedicated to transforming microbiological quality control within the pharmaceutical and biotechnology sectors. The company leverages cutting-edge automated growth-based microbial detection technologies to enhance the accuracy and efficiency of microbial testing, thereby ensuring stringent product quality and compliance with regulatory standards. Positioned at the forefront of an expanding market that demands swift and dependable quality assurance solutions, Rapid Micro is poised to lead the advancement of innovative testing methodologies critical to maintaining safety and excellence in regulated environments.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?